Detalhe da pesquisa
1.
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
Blood
; 142(14): 1208-1218, 2023 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366170
2.
mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin-mediated amyloidosis.
Muscle Nerve
; 62(4): 502-508, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32654212
3.
Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis.
Muscle Nerve
; 62(4): 509-515, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32654156
4.
Burden of hereditary transthyretin amyloidosis on quality of life.
Muscle Nerve
; 60(2): 169-175, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31093980
5.
A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time.
Br J Haematol
; 179(3): 461-470, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28850697
6.
Cardiac biomarkers and health-related quality of life in patients with light chain (AL) amyloidosis.
Br J Haematol
; 185(5): 998-1001, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30467849
7.
Cardiac Amyloid Detection by PET/CT Imaging of Iodine (124I) Evuzamitide (124I-p5+14): A Phase 1/2 Study.
JACC Cardiovasc Imaging
; 16(11): 1433-1448, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37940323
8.
Clinical Confirmation of Pan-Amyloid Reactivity of Radioiodinated Peptide 124I-p5+14 (AT-01) in Patients with Diverse Types of Systemic Amyloidosis Demonstrated by PET/CT Imaging.
Pharmaceuticals (Basel)
; 16(4)2023 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37111386
9.
Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being.
J Patient Rep Outcomes
; 5(1): 3, 2021 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33411323
10.
The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data.
Neurol Ther
; 9(2): 473-482, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32451849
11.
Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis.
J Neurol
; 267(4): 1070-1079, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31853709
12.
Epidemiology of AL amyloidosis: a real-world study using US claims data.
Blood Adv
; 2(10): 1046-1053, 2018 05 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29748430
13.
Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data.
J Comp Eff Res
; 7(6): 549-559, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29390860
14.
Light Chain (AL) Amyloidosis: The Journey to Diagnosis.
Patient
; 11(2): 207-216, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28808991
15.
Treatment Tolerability in Patients with Immunoglobulin Light-Chain Amyloidosis.
Am Health Drug Benefits
; 11(8): 430-437, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30647830
16.
Longitudinal PET/CT imaging with iodine (124I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis.
Amyloid
; : 1-2, 2023 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37990984
17.
The burden of amyloid light chain amyloidosis on health-related quality of life.
Orphanet J Rare Dis
; 12(1): 15, 2017 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-28103898
18.
Content validation of the SF-36v2® health survey with AL amyloidosis patients.
J Patient Rep Outcomes
; 1(1): 13, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29757308
19.
Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples.
Patient Relat Outcome Meas
; 8: 157-167, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29263707
20.
Primary Amyloidosis With Renal Involvement: Outcomes in 77 Consecutive Patients at a Single Center.
Clin Lymphoma Myeloma Leuk
; 17(11): 759-766, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28689003